



---

One North End Avenue \_ Suite 1111 \_ New York \_ New York 10282  
Telephone: (877) 898-8038 (212) 791-2911 Fax: 212-791-2917  
150 Fairway Drive \_ Suite 150 \_ Vernon Hills \_ Illinois 60061  
Telephone: (847) 573-0033 \_ Facsimile: (847) 573-8288  
(Amex-IMM)

CONTACT: F. C. Thompson: 877-898-8038

## **IMMTECH INVESTOR CONFERENCE CALL SCHEDULED FOR TUESDAY, JULY 25, 2006**

New York, NY, July 21, 2006 - Immtech Pharmaceuticals, Inc. (AMEX: IMM) announced today that the Company will hold a conference call on Tuesday, July 25, 2006 at 5:00 p.m. EST. to present an update on the Company's progress. Investors and interested parties are invited to join the call by dialing (877) 497-0736 and registering with the operator. Please call no later than 10 minutes prior to the scheduled start of the call to register.

### **About Immtech Pharmaceuticals**

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new treatments for malaria, Pneumocystis pneumonia and African sleeping sickness (Trypanosomiasis) and drug development programs for fungal infections, hepatitis C, and tuberculosis. The Company has worldwide licensing and exclusive commercialization rights to a large library of well-defined compounds from which a pipeline of therapeutic products could be developed. For additional information, please go to <http://www.immtechpharma.com>.

“Safe Harbor” Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.’s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report on Form 10-K for the most recently ended fiscal year.